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Harnessing Information Technology to Inform Patients 
Facing Routine Decisions: Cancer Screening as a Test Case
ABSTRACT
PURPOSE Technology could transform routine decision making by anticipating 
patients’ information needs, assessing where patients are with decisions and 
preferences, personalizing educational experiences, facilitating patient-clinician 
information exchange, and supporting follow-up. This study evaluated whether 
patients and clinicians will use such a decision module and its impact on care, 
using 3 cancer screening decisions as test cases.
METHODS Twelve practices with 55,453 patients using a patient portal partici-
pated in this prospective observational cohort study. Participation was open to 
patients who might face a cancer screening decision: women aged 40 to 49 who 
had not had a mammogram in 2 years, men aged 55 to 69 who had not had a 
prostate-specific antigen test in 2 years, and adults aged 50 to 74 overdue for 
colorectal cancer screening. Data sources included module responses, electronic 
health record data, and a postencounter survey.
RESULTS In 1 year, one-fifth of the portal users (11,458 patients) faced a poten-
tial cancer screening decision. Among these patients, 20.6% started and 7.9% 
completed the decision module. Fully 47.2% of module completers shared 
responses with their clinician. After their next office visit, 57.8% of those sur-
veyed thought their clinician had seen their responses, and many reported the 
module made their appointment more productive (40.7%), helped engage them 
in the decision (47.7%), broadened their knowledge (48.1%), and improved com-
munication (37.5%).
CONCLUSIONS Many patients face decisions that can be anticipated and proac-
tively facilitated through technology. Although use of technology has the poten-
tial to make visits more efficient and effective, cultural, workflow, and technical 
changes are needed before it could be widely disseminated.
Ann Fam Med 2017;15:217-224. https://doi.org/10.1370/afm.2063.
INTRODUCTION
Today’s patients face complex medical decisions. Clinicians tradi-tionally support patients with decisions by giving advice during in-person visits. Unfortunately, the competing demands and time con-
straints associated with office visits limit the help clinicians can realistically 
provide.1,2 More importantly, both difficult and even routine choices might 
entail a “decision journey”—that is, the support required may extend over 
time, a period during which patients may contemplate options, gather 
additional information, confer with family and friends, consider personal 
preferences, and address worries or concerns.3-5 These tasks are beyond 
what can be accomplished during an office visit.6-9
Although the components of a “good” medical decision journey have 
been well described,10-13 patients generally receive limited support dur-
ing these journeys.14-17 Patients want to be included in decisions, yet 
many decisions occur with minimal patient input.17-19 When conversations 
do take place, they rarely include all elements needed for an informed 
decision.14,18,20 One proven solution is to use decision aids. Decision 
aids increase knowledge, reduce decisional conflict, engage patients, 
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and reduce rates of elective invasive procedures and 
unnecessary testing.21-23 Yet it is difficult for clinicians 
to routinely use decision aids, and accordingly, they 
are not commonly used.24-29
Health information technology (HIT) offers a 
potential to systematically automate decision-making 
processes outside the constraints of clinical encoun-
ters. This strategy could enable visits with clinicians 
to focus on decision elements that occur best in per-
son.30,31 HIT has the capacity to anticipate decision 
needs through programmed logic, deliver information 
and decision support before visits, collect patient-
reported information, share information with the cli-
nician about where the patient is with decisions and 
preferences, set a decision-making agenda, and even 
follow up on next steps (Figure 1).
METHODS
This pragmatic observational cohort study evaluated 
how clinicians and patients used an integrated decision 
module and explored the module’s impact on care for 3 
routine decision scenarios: when to start breast cancer 
screening, how to be screened for colorectal cancer, 
and not being screened for prostate cancer. These 3 
screening topics were selected because they represent 
common patient decisions—even prostate cancer 
screening, which although not recommended for the 
general population, is often inquired about by patients 
and may be appropriate for a subset of men willing 
to risk screening harms.32 The study was reviewed by 
the Virginia Commonwealth University Institutional 
Review Board (HM14750).
Setting
Twelve primary care practices in northern Virginia 
participated. The practices shared 1 of 2 electronic 
health records (EHRs), Allscripts Enterprise or Pro-
fessional. All practices used a central patient portal, 
called MyPreventiveCare.33 At the time of the study, 
55,453 unique patients (34.5% of the practice popula-
tion) had a portal account and 23,546 used the portal 
during the study period. Although portal users were 
representative of the practices, prior investigation 
demonstrated users were more likely to be older or 
have comorbidities, and were slightly less likely to be 
African American or Hispanic.34
Participants
Patients age 50 to 75 years who were overdue for 
colorectal cancer screening,35 women aged 40 to 49 
years who had not had a mammogram in 2 years, 
and men aged 55 to 69 years who had not obtained 
a prostate-specific antigen (PSA) test in 2 years were 
invited to complete the decision module. Patients 
were excluded if they had a prior diagnosis of 
colorectal, breast, or prostate cancer, or prior abnor-
mal screening test results.
Invitations to use the module occurred in 3 phases. 
In phase 1 (January 6, 2014, through February 16, 
2014), eligible patients who logged into the portal were 
prompted to review the module. In phase 2 (February 
17, 2014, through May 15, 2014), eligible patients who 
had a visit scheduled 2 weeks in advance were e-mailed 
an invitation to review the module, 2 weeks, 1 week, 
and 2 days before their visit. In phase 3 (May 26, 2014, 
through August 15, 2014), any eligible patient was 
Figure 1. Conceptual model for engaging patients through an informed decision-making module 
embedded in a patient portal and electronic health record. 
Note: To engage patients in their decision, the informed decision-making (IDM) module guides patients and clinicians through a series of 7 steps that can be applied to 
a wide range of decisions beyond the test case (cancer screening) investigated in this study. The IDM module (1) reaches patients outside the confines of an office visit 
to explore a potential decision by completing the module; (2) walks patients through an intake that assesses personal preferences, knowledge, and needs, and patients’ 
readiness to make a decision; (3) provides personalized educational material tailored to patients’ stated preferences and decision stage; (4) allows patients to share their 
preferences and decision needs with their clinician; (5) prompts patients and clinicians to use the reported information to make a decision; (6) guides the patient to 
make a choice, which can include deferring the decision; and (7) invites patients and clinicians to provide input after the encounter.
2. Preference 
questions
3. Personalized edu-
cational material
7. Postencounter patient and 
clinician input and follow-up
1. Patient with decision 
needs identi ed
Module assessment 
and education
4. Information sharing 
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e-mailed up to 3 weekly invitations to review the mod-
ule, irrespective of appointment status.
Decision Module
The decision module promoted the 2012 prostate, 
2009 breast, and 2008 colon cancer screening rec-
ommendations made by the US Preventive Services 
Task Force.32,35,36 It included 7 components (Figure 1). 
The system identified eligible patients through well-
established programmed logic by querying the EHR 
and portal data.33 It flagged eligible patients when they 
used the portal (phase 1) or during a daily scheduled 
query (phases 2 and 3) and then invited patients by 
prompt or e-mail to complete a previsit assessment in 
the decision module. Seventeen interactive questions 
explored patients’ stage of readiness for deciding about 
cancer screening, information needs and fears, desired 
assistance, preferred format for receiving information 
and statistics, and planned next steps.
Based on patients’ responses, the module assembled 
a customized educational page that included informa-
tion about topics of greatest interest to patients (eg, 
risk of cancer, benefits or harms of screening, screening 
logistics) in the format they preferred (ie, words, num-
bers, pictures, or stories). Questions were derived from 
validated instruments when possible.37-39
The module asked patients if they would like to 
discuss screening at their next office visit and if they 
would like a summary to be automatically forwarded 
to their clinician for review. The summary included 
whether patients had made a screening decision, the 
topics they wanted to discuss, their fears and wor-
ries, and their preferred level of decision control.37 
Supplemental Appendix 1, available at http://www.
annfammed.org/content/15/3/217/
suppl/DC1/, displays screenshots 
of MyQuestions, educational 
content, and clinician summaries. 
The system automatically sent 
a postencounter questionnaire 
to both the patient and clini-
cian after the office visit. The 
questionnaire sought feedback 
on the module and the events 
before, during, and after the clini-
cal encounter. Nonresponders 
received up to 5 reminders.
The design of the module was 
informed by a 2-year process of 
patient and stakeholder engage-
ment including focus groups 
to identify important module 
content; patient iterative input of 
draft module content; cognitive 
and usability testing consistent 
with national standards40; and 
a patient, clinician, and health 
system workgroup that met quar-
terly for 2 years to help plan the 
decision module design, imple-
mentation, and interpretation of 
findings.41 A clinician from each 
practice served on the clinician 
workgroup and helped to stan-
dardize and promote implemen-
tation at his or her office.
Outcomes
Primary outcomes included 
measures of how the decision 
module was used and its impact 
Table 1. Patients Starting and Completing the Informed Decision-
Making Module by Study Phase and Cancer Screening Decision
Module Use
Cancer Screening Decision
Colon Breast Prostate Total
Overall use: phases  
1, 2, and 3 combineda
Eligible, No. 6,329 3,733 1,396 11,458
Starters, No. (%) 1,249 (19.7) 638 (17.1) 468 (33.5) 2,355 (20.6)
Completers, No.
Of starters, % 
Of eligible, %
489
39.2 
7.7
190
9.8 
5.1
224
47.9 
6.0
903
38.3
7.9
Phase 1: prompt on  
MyPreventiveCare log-ina
Eligible, No. 542 297 171 1,010
Starters, No. (%) 154 (28.4) 70 (23.6) 86 (50.3) 310 (30.7)
Completers, No.
Of starters, % 
Of eligible, %
39 
25.3
7.2
12 
17.1 
4.0
21 
24.4 
12.3
72 
23.2 
7.1
Phase 2: prompt via e-mail 
before appointmenta 
Eligible, No. 354 171 85 610
Starters, No. (%) 140 (39.5) 53 (31) 53 (62.4) 246 (40.3)
Completers, No.
Of starters, % 
Of eligible, %
75
53.6 
21.2
19
35.9
11.1
35
66.0
41.2
129
52.4
21.1
Phase 3: prompt via e-mail 
without an appointmenta
Eligible, No. 5,136 3,220 1,080 9,436
Starters, No. (%) 469 (9.1) 264 (8.2) 189 (17.5) 922 (9.8)
Completers, No.
Of starters, % 
Of eligible, %
174 
37.1 
3.4
77 
29.2 
2.4
87 
46.0 
8.1
338 
36.7
3.6
a Phases 1, 2, and 3 combined: January 2, 2014, through August 15, 2014. Phase 1: January 2, 2014, through 
February 16, 2014. Phase 2: February 17, 2014, through May 25, 2014. Phase 3: May 26, 2014, through 
August 15, 2014.
Note: The difference in starting and completing the decision module was statistically different for breast vs 
colorectal (P =.001), breast vs prostate (P <.001), and colorectal vs prostate cancer (P <.001) screening deci-
sions. The difference in starting and completing the decision module was statistically different for phase 1 vs 
phase 2 (P <.001), phase 1 vs phase 3 (P <.001), and phase 2 vs phase 3 (P <.001).
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on decision making. We used 5 data sources: (1) the 
EHR (demographics, diagnoses, screening status, mod-
ule eligibility), (2) the portal (health risk assessment 
responses, prompt, or e-mail invitation receipt), (3) the 
decision module (patients’ responses, paradata–clicks 
within the decision module pertaining to use of edu-
cational materials),42,43 and (4) the patient postencoun-
ter questionnaire and (5) the clinician postencounter 
questionnaire (see Supplemental Appendices 2 and 3, 
respectively, for the questionnaires, available at http://
www.annfammed.org/content/15/3/217/suppl/DC1/).
Decision module uptake—measured by the num-
ber of eligible patients who started and completed the 
module—was calculated by race, ethnicity, sex, pre-
ferred language, insurance type, and phase of module 
invitation. Measures of module use included educa-
tional content patients reviewed (paradata), whether 
patients elected to share responses with their clinician, 
and whether patients believed their clinician reviewed 
their forwarded summary. EHR data indicated whether 
patients obtained breast, colorectal, or prostate screen-
ing within 3 months of using the module.
Analysis
The analysis included all patients with a 
MyPreventiveCare account who met eli-
gibility criteria. Patients were subdivided 
into starters and nonstarters, and starters 
were further subdivided into completers or 
noncompleters. We used χ2 tests for inde-
pendent group comparisons, generalized 
linear mixed models (GLMMs) for depen-
dent group comparisons, and ANOVA 
to compare time to follow-up between 
groups. We used a GLMM when compar-
ing phase eligibility to include a patient-
level random effect that accounted for 
patients being eligible in multiple phases. 
We did not adjust for other covariates. All 
analyses were completed using SAS ver-
sion 9.4 (SAS Institute). 
RESULTS
Decision Module Use
During the nearly 1-year study period, 
11,458 patients (20.7% of 55,453 unique 
portal users) faced a screening decision for 
colorectal cancer (6,329 patients), breast 
cancer (3,733 patients), or prostate cancer 
(1,396 patients) (Table 1). Prompted by the 
invitation, 2,355 patients started and 903 
completed the module. Patients faced with 
a prostate cancer screening decision were 
most likely, while patients faced with breast cancer 
screening were least likely, to start and complete the 
module (P <.001).
Patients eligible in phase 2 were most likely to 
start the module (phase 1, 2, and 3 = 20.6%, 30.7%, 
and 9.8%, P <.001) and complete the module (phase 1, 
2, and 3 = 7.9%, 21.1%, and 3.6%, P <.001) (Table 1). 
Although phase 3 had the lowest percentage of starters 
and completers, because many patients were included 
in phase 3, it yielded the largest absolute number of 
starters and completers. A detailed analysis of module 
attrition has been previously reported.44
When the module was used, paradata indicated that 
291 patients (23.6%) clicked on at least 1 educational 
resource in the module (Supplemental Appendix 1, 
section 16)—an average of 3.5 resources per patient. 
The most frequent information patients reviewed 
were options for getting screened (206 patients, 
70.8%), what screening test works best (145 patients, 
49.8%), problems or complications from screening 
(133 patients, 45.7%), and how the test is performed 
(120 patients, 41.2%). Among the 1,044 patients who 
Table 2. Use of the Informed Decision-Making Module by 
Demographic Characteristics
Characteristic
Module Starters Module 
NonstartersNoncompleters Completers
Age, mean (SD), y 53.5 (8.3) 54.9 (8.2) 52.4 (8.2)
Total, No. (%) 1,452 (12.7) 903 (7.9) 9,103 (79.4)
Sex
Male
Female
595 (13.9)
857 (11.9)
472 (11.1)
431 (6.0)
3,201 (75.0)
5,902 (82.1)
Race, No. (%)
Asian 
African American 
White 
Other
Unreported
132 (11.4)
62 (12.6)
1,019 (13.7)
67 (11.7)
172 (9.5)
60 (5.2)
63 (12.8)
618 (8.3)
43 (7.5)
119 (6.6)
966 (83.4)
368 (74.6)
5,788 (78.0)
464 (80.8)
1,517 (83.9)
Ethnicity, No. (%)
Hispanic
Non-Hispanic
Unknown
43 (9.7)
1,065 (13.5)
344 (11.0)
38 (8.5)
658 (8.4)
207 (6.6)
364 (81.8)
6,153 (78.1)
2,586 (82.4)
Language, No. (%)
English
Other
1,249 (13.3)
203 (9.8)
770 (8.2)
133 (6.5)
7,375 (78.5)
1,728 (83.7)
Insurance type, No. (%)
Commercial 
Medicare
Medicaid 
None
1,304 (13.8)
92 (17.2)
1 (20.0)
55 (3.7)
782 (8.3)
69 (12.9)
0 (0)
52 (3.5)
7,349 (77.9)
374 (69.9)
4 (80.0)
1,376 (92.8)
Prior screening, No. (%)
Yes
No
538 (14.3)
914 (11.9)
347 (9.3)
556 (7.2)
2,861 (76.4)
6,242 (80.9)
Note: Given the large sample size, all differences across groups (noncompleters, completers, and 
nonstarters) were statistically significant (P <.001) with the exception of Medicaid insurance type.
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reached the forwarding question, 493 (47.2%) indicated 
a desire to forward a summary to their clinician.
Characteristics of Decision Module Users
Women were less likely than men to use the module 
(Table 2). Within the colorectal cancer screening 
cohort, which included both sexes, more men started 
the module (P =.03). Similarly, across all phases, men 
were more likely than women to share a summary with 
their clinician (56.3% vs 37.0%, P <.001). Module use 
was lower for patients with no prior screening than 
for those previously screened 
(P <.001) and for patients who 
preferred a language other 
than English (P <.001). His-
panics tended to be less likely 
than non-Hispanics to start 
the module (P =.07). Factors 
other than socioeconomic status 
also appeared important. Asian 
patients, a demographic with 
often high socioeconomic sta-
tus,45 were least likely to start the 
module (P <.001), and African 
American patients were most 
likely to complete it (P <.001). 
Start and completion rates were 
higher for Medicare beneficiaries 
than for commercially insured 
patients (P <.001).
Impact on Care
The next office visit occurred, 
on average, 50 days (range, 0-312 
days) after the decision module 
session. The average differed by 
phase (phase 1 = 160 days, phase 
2 = 7 days, and phase 3 = 14 days; 
P <.001), although some patients 
in each phase did not have a visit 
after module use. About 50% to 
60% of patients and clinicians 
reported the clinician reviewed 
the forwarded summary before the 
visit. Patients reported that screen-
ing was discussed more often 
during wellness visits than during 
chronic or acute care visits (82.5%, 
63.9%, 60.0%, respectively, P 
=.03) (Table 3). Patients who for-
warded a summary were slightly 
more likely to report discussion of 
screening than those who did not 
(72.9% vs 67.7%, P =.04).
A sizable subset of patients and clinicians (30% 
to 50%) reported that the module prompted can-
cer screening discussions, helped patients get more 
involved, improved knowledge, enhanced commu-
nication, made clinicians more sensitive to patients’ 
concerns, and facilitated decisions (Table 3). Although 
only 39.0% of clinicians recalled addressing the 
patient’s fears/worries, 80.9% of patients said the clini-
cian helped reduce their fears/worries.
Module completion was associated with screening 
behavior (Figure 2): completers were more likely to 
Table 3. Satisfaction With the Informed Decision-Making Module and 
Reported Impact on Care
Statement or Measure
Patient 
Agreement, % 
(n = 277)a
Clinician 
Agreement, % 
(n = 281)b
Doctor believed to have seen response summary  
at time of appointment
Yes
No
Cannot remember
57.8
21.1
21.1
50.0
50.0
0
Doctor discussed screening test at visit
Yes
No
Cannot remember
70.7
20.7
8.6
65.5
24.6
9.9
How use of module changed the conversation
Motivated patient to talk with doctor
Prompted doctor to talk with patient
Did not change anything
Other
39.0
28.1
47.3
2.1
41.3
39.7
33.3
9.5
How conversation helped patient with fears or  
worries ranked as most important on module
Reduced fears or worries
Did not help with fears or worries
80.9
19.1
NA
NA
Doctor recalled addressing patients’ fears or worries 
about cancer screening
Yes
No
Cannot remember
NA
NA
NA
39.0
29.3
31.7
Strongly/somewhat agree vs strongly/somewhat 
disagree regarding completion of module and 
forwarding of summaryc
Look and layout were easy to understand
Took too long to complete
Was easy to complete
Helped patient with cancer screening decision
Made visit more productive
Got patient more involved with the decision
Helped to change patient’s screening plans
Improved patient-doctor communication
Improved patient’s knowledge before visit
Made the doctor more sensitive to patient’s needs
56.0 vs 9.7
34.3 vs 29.2
72.2 vs 11.1
42.6 vs 20.4
40.7 vs 17.6
47.7 vs 17.6
22.7 vs 30.1
37.5 vs 16.7
48.1 vs 15.7
27.3 vs 11.6
NA
NA
NA
44.9 vs 8.2
38.1 vs 16.3
51.7 vs 6.1
13.6 vs 17.0
42.2 vs 12.2
45.6 vs 6.1
48.3 vs 10.2
NA = not applicable.
a Response rate = 44.7%.
b Response rate = 45.3%.
c Response options were strongly agree, somewhat agree, neither agree nor disagree, somewhat disagree, and 
strongly disagree. Values for neither agree nor disagree are not reported in table.
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get screened within 3 months than nonstarters and 
noncompleters (P <.001), a pattern suggesting that 
they had already made a screening choice—mostly to 
get screened. Among patients eligible for colon cancer 
screening, completers were more likely than nonstart-
ers to get a colonoscopy (P <.001) or a stool test 
(P <.001). Comparing nonstarters with completers, 
there was a greater increase in colonoscopies than 
stool tests for the latter (P <.001).
DISCUSSION
This pragmatic observational cohort study harnessed 
EHR data and patient portal capabilities to create 
an automated decision module that could identify 
patients likely to be facing common cancer screen-
ing decisions, engage and inform patients, clarify 
questions and fears, identify next decision steps, and 
improve the decision-making process. We found that 
practices had large decision burdens—with 1 in 5 
patients facing a decision—yet only 20.6% of patients 
facing a decision started and 7.9% completed our 
decision module. Users reviewed a range of topics, 
and one-half of patients forwarded their priorities and 
concerns to clinicians. Both patients and clinicians 
reported that module completion helped with deci-
sions: one-third to one-half reported it made appoint-
ments more productive, got patients more involved 
in decisions, broadened knowledge, and improved 
communication.
Our proposed decision module is appealing, yet a 
clear challenge is getting patients to use such a system. 
Decision support use is high in the context of clinical 
trials.23,25 Routine use of decision support in clinical 
practice, which we tried to automate in this study, is 
low (9% to 10% of encounters in implementation tri-
als), however.26 Furthermore, pragmatic trials looking 
at patient portal use frequently demonstrate low initial 
Figure 2. Relationship of the informed decision-making module with follow-up visits and with breast, 
colorectal, and prostate cancer screening. 
PSA = prostate-specific antigen. 
Note: Percentages of patients who received screening tests were derived from electronic health record data for a period of 3 months after completion of the decision 
module. Although the colorectal cancer screening rate appears low, this study included only the subset of practice patients overdue for that screening. On the basis of 
prior studies and practice quality program participation, about 70% of patients in the study practices have been screened for colorectal cancer.46
11,458 Patients with potential 
screening decision
20.6% Module starters
38.3% Module completers 61.7% Module noncompleters
51.7% Didn’t share summary 
with clinician
48.3% Shared summary 
with clinician
19.8% Wellness visit
24.6%  Chronic care 
visit
9.9%  Acute care 
visit
91.6% Didn’t share summary 
with clinician
3.9% Shared summary 
with clinician
45.7% No 
follow-up visit
79.4% Module nonstarters
0.6% Mammogram
0.0% PSA test
0.7% Colonoscopy
0.0% Stool test
12.8% Mammogram
14.3% PSA test
7.9% Colonoscopy
4.6% Stool test
31.3% No 
follow-up visit
21.5% Wellness visit
24.6%  Chronic care 
visit
22.5%  Acute care visit
22.0% Mammogram
18.8% PSA test
16.9% Colonoscopy
5.9% Stool test
17.2% Mammogram
6.3% PSA test
11.1% Colonoscopy
3.2% Stool test
30.7% Mammogram
35.5% PSA test
17.1% Colonoscopy
6.8% Stool test
15.7% Mammogram
8.7% PSA test
15.9% Colonoscopy
5.3% Stool test
14.1% Wellness visit
18.1%  Chronic care 
visit
13.2%  Acute care 
visit
54.6% No 
follow-up visit
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uptake with increasing use over time as the portal 
becomes part of new standard workflows.47,48
Our findings regarding patient use by phase provide 
some insight into how such systems could be integrated 
into workflow. Linking invitations to visits (phase 2) 
resulted in greater response rates and less time between 
portal use and visits; inviting anyone with a need (phase 
3) resulted in a greater absolute number of users and 
may have prompted needed visits. Findings further 
suggest some groups of patients (possibly men more 
than women and African Americans more than Asians) 
and types of decisions (prostate cancer screening more 
than breast cancer screening) may derive greater ben-
efit from a decision module, but comparison trials are 
needed to fully understand these observations.
Most trials of traditional decision aids demonstrate 
reduced use of services with marginal benefit and 
increased use of beneficial services.23,49-52 Although 
Figure 2 shows decision module users had higher rates 
of breast and prostate cancer screening, which may 
not be good for screening services with small or zero 
net benefit, users self-selected, and module responses 
indicated a substantial proportion were already 
inclined to be screened. Randomized controlled trials 
of similar systems and trials that assess whether deci-
sions better align with values are needed. Additionally, 
longer observational periods are required to see the 
full increase on desired colorectal cancer screening.
This feasibility study had limitations. It involved a 
large population but lacked controls. It relied on surveys 
to gauge associations. Completers were more likely to 
be screened, but this self-selected sample may have been 
more motivated than other patients. We conducted 
paired postencounter surveys to elicit feedback from 
patients and clinicians after visits; overall response rates 
were 45%, and the rate of paired responses was lower.
Confirming this study’s findings in controlled tri-
als will be important and has implications well beyond 
cancer screening. Health systems and payers could 
expand the role of portals to help patients prepare for 
other complex decisions. Implementing this model 
of using technology for decision making is likely to 
encounter technologic challenges,53-56 and engag-
ing patients online and integrating the process with 
practice workflow may not be easy. If, however, future 
research confirms the benefits of this approach—more 
informed patients, better decisions, and wiser use of 
encounter time—the return on investment could offset 
the implementation costs and improve care.
To read or post commentaries in response to this article, see it 
online at http://www.AnnFamMed.org/content/15/3/217.
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